- Moderna has opened the Moderna Innovation and Technology Centre (MITC) at Harwell Science and Innovation Campus, Oxfordshire, to produce mRNA respiratory vaccines for the UK.
- The site can produce up to 100 million doses annually, with capacity to scale to 250 million in a pandemic, and will support research in cancer, rare diseases, and immune disorders.
Moderna has officially launched its Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK. The facility will manufacture British-made mRNA respiratory vaccines to support the National Health Service (NHS) seasonal vaccination programmes.
The MITC is designed to produce up to 100 million vaccine doses per year, with the potential to scale to 250 million doses during a pandemic. It also includes a Clinical R&D laboratory that will analyse samples from Moderna’s global clinical trials.
“The opening of the Moderna Innovation and Technology Centre marks the first facility in the UK to manufacture an onshore supply of mRNA vaccines.” He noted that the company’s partnership with the UK has delivered over 20 clinical trials across 110 sites nationwide.
Stéphane Bancel, Chief Executive Officer of Moderna
Beyond respiratory vaccines, the MITC will support research into the applications of mRNA science in cancer, rare diseases, and immune disorders. The facility forms part of Moderna’s global network of advanced manufacturing hubs, which includes sites in Australia and Canada, aiming to strengthen pandemic readiness.
